## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
--

FORM 4

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						2. Issuer Name and Ticker or Trading Symbol <u>Landos Biopharma, Inc.</u> [LABP]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify					
(Last) (First) (Middle) 40 10TH AVENUE, FLOOR 7						3. Date of Earliest Transaction (Month/Day/Year) 02/04/2021									below)	jive uue		below)	specity	
(Street) NEW YORK NY 10014					4. lf /	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					
(City) (State) (Zip)																				
			Table I - Nor	1-Deri	/ative	e Se	ecu	rities Acc	quired,	Dis	posed o	f, or	Bene	ficially (	Owned					
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date,		ution Date, y	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 a						6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount		(A) or (D)	Price	(Instr. 3 and 4)				(		
Common Stock 02/04/				/2021	)21		Р		625,00	625,000 A		\$1 <mark>6</mark>	625,000 <sup>(1)</sup>		Ι		By RTW <sup>(2)</sup>			
Common Stock 02/08/				8/2021	2021			С		3,650,7	),722 A		(3)	4,275,722 <sup>(1)(4)</sup>			I	By RTW <sup>(2)</sup>		
			Table II -					ties Acqu warrants,							vned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	4. Transaction Code (Instr.			Derivative		6. Date Exercis Expiration Date (Month/Day/Ye		sable and 7. te Sear) D			amount of nderlying ecurity 4)	8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin	ve es ally Ig	10. Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)	
				Cod	e v	(,	(A) (	(D)	Date Exercisa	able	Expiration Date	Title	N	mount or umber of hares		Reporte Transac (Instr. 4)	tion(s)			
Series B Preferred Stock	(3)	02/08/2021		с			3	3,650,722 <sup>(3)</sup>	(3)		(3)		nmon ock 3	,650,722	(3)	0		I	By RTW <sup>(2)</sup>	
1. Name and Address of Reporting Person <sup>*</sup> <u>RTW INVESTMENTS, LP</u>																				
(Last)(First)(Middle)40 10TH AVENUE, FLOOR 7			)																	
(Street) NEW YORK NY 10014																				
(City)		(State)	(Zip)																	
	nd Address of GRODEF	Reporting Person <sup>*</sup>				_														
(Last)(First)(Middle)C/O RTW INVESTMENTS, LP40 10TH AVENUE, FLOOR 7																				
(Street) NEW Y	ORK	NY	10014																	
(City)		(State)	(Zip)																	
•	n of Respons	<b>ses:</b> 1mon stock held by R	TW Master Fund.	Ltd., RT	W Venti	ıre F	Fund I	Limited and R	TW Inno	vation	Master Fund	l. Ltd.	(the "RT	W Funds")						

2. The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by the RTW Funds, which are investment funds managed by RTW, and (ii) Roderick Wong, M.D., who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the RTW Funds, except to the extent of its or his pecuniary interest therein.

3. Each share of the Issuer's Series B preferred stock automatically converted into 1.8249 shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering. The Series B preferred stock had no expiration date.

4. Reflects a 1.8249-for-1 stock split of the Issuer's common stock effected on January 29, 2021.

RTW Investments, LP By: /s/ Roderick Wong, Managing 02/08/2021 **Partner** Roderick Wong By: /s/ Roderick 02/08/2021 <u>Wong</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.